The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
暂无分享,去创建一个
[1] L. Saal,et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.
[2] N. Ellis,et al. Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells. , 2001, Genes & development.
[3] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.
[4] T. Ludwig,et al. BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity , 2011, Science.
[5] Cuk-Seong Kim,et al. SIRT1 deacetylates APE1 and regulates cellular base excision repair , 2009, Nucleic acids research.
[6] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[7] J. Glover,et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. , 2010, Cancer research.
[8] D. Adams,et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers , 2010, Nature Structural &Molecular Biology.
[9] T. Helleday,et al. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair , 2006, Nucleic acids research.
[10] Jiri Bartek,et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer , 2002, Nature Cell Biology.
[11] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.
[12] S. Elledge,et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.
[13] N. de Wind,et al. A cell‐free assay for the functional analysis of variants of the mismatch repair protein MLH1 , 2010, Human mutation.
[14] S. Elledge,et al. A DNA Damage Response Screen Identifies RHINO, a 9-1-1 and TopBP1 Interacting Protein Required for ATR Signaling , 2011, Science.
[15] L. Kèlland,et al. The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.
[16] W. Foulkes,et al. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? , 2011, Journal of Clinical Pathology.
[17] J. Aten,et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. , 2010, Cancer cell.
[18] R. Kanaar,et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition , 2011, Proceedings of the National Academy of Sciences.
[19] Jos Jonkers,et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer , 2007, Proceedings of the National Academy of Sciences.
[20] Andrew J. Wilson,et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. , 2010, Cancer cell.
[21] M. J. van de Vijver,et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Junjie Chen,et al. PALB2 is an integral component of the BRCA complex required for homologous recombination repair , 2009, Proceedings of the National Academy of Sciences.
[23] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] Heidi Ledford. Drug candidates derailed in case of mistaken identity , 2012, Nature.
[25] Hans Joenje,et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2 , 2007, Nature Genetics.
[26] D. Adams,et al. A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors , 2009, Clinical Cancer Research.
[27] M. Guenther,et al. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response , 2003, The Journal of cell biology.
[28] Nicole Bennardo,et al. Limiting the Persistence of a Chromosome Break Diminishes Its Mutagenic Potential , 2009, PLoS genetics.
[29] N. de Wind,et al. A rapid and cell‐free assay to test the activity of lynch syndrome‐associated MSH2 and MSH6 missense variants , 2012, Human mutation.
[30] E. Sausville,et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. , 1996, Journal of the National Cancer Institute.
[31] Jianyuan Luo,et al. SIRT1 regulates UV-induced DNA repair through deacetylating XPA. , 2010, Molecular cell.
[32] R. Syljuåsen,et al. A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance , 2011, EMBO reports.
[33] Pingfang Liu,et al. Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6 , 2006, Cell.
[34] F. Alt,et al. Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. , 2007, Molecular cell.
[35] C. Mathew,et al. Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism , 1999, Nature Genetics.
[36] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[37] Katherine S. Lovejoy,et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. , 2010, Genes & development.
[38] Robert Almassy,et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. , 2004, Journal of the National Cancer Institute.
[39] A. Levine,et al. The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.
[40] W. Richard McCombie,et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo , 2008, Proceedings of the National Academy of Sciences.
[41] A. Ashworth,et al. Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.
[42] B. Karlan,et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.
[43] M. Hemann,et al. Error-prone translesion synthesis mediates acquired chemoresistance , 2010, Proceedings of the National Academy of Sciences.
[44] S. Carr,et al. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. , 2010, Molecular cell.
[45] Lenie J. van den Broek,et al. Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}. , 2010, Cancer research.
[46] A. Chapelle,et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability , 1995, Nature Genetics.
[47] Peter A. Jones,et al. A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.
[48] M. Jasin,et al. BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.
[49] Carlos Cordon-Cardo,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.
[50] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[51] P. Mitra,et al. Targeting base excision repair for chemosensitization. , 2008, Anti-cancer agents in medicinal chemistry.
[52] F. Couch,et al. Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma , 2022 .
[53] A. Nussenzweig,et al. DNA damage-induced G2–M checkpoint activation by histone H2AX and 53BP1 , 2002, Nature Cell Biology.
[54] B. Gusterson,et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.
[55] D. Cortez,et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. , 2008, Molecular cell.
[56] Joshua E. Elias,et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers , 2011, Nature.
[57] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[58] A. Lau,et al. Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin , 2008, Clinical Cancer Research.
[59] Gerard I. Evan,et al. Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.
[60] Yun Dai,et al. New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.
[61] Darryl Shibata,et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.
[62] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[63] H. Niida,et al. Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo , 2010, The EMBO journal.
[64] S. Cantor,et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. , 2005, Cancer cell.
[65] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[66] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[67] Rochelle L. Garcia,et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] A. Harris,et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. , 2010, Cancer research.
[69] S. Elledge,et al. The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.
[70] S. Jackson,et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining , 2010, Nature Structural &Molecular Biology.
[71] C. Mathew,et al. Somatic Mosaicism in Fanconi Anemia: Molecular Basis and Clinical Significance , 1997, European journal of human genetics : EJHG.
[72] A. Ashworth,et al. A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.
[73] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[74] P. Borst,et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.
[75] T. Hamilton,et al. Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.
[76] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[77] Jung-Sik Kim,et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.
[78] S. Jentsch,et al. Principles of ubiquitin and SUMO modifications in DNA repair , 2009, Nature.
[79] A. Spurdle,et al. Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1 , 2008, Breast Cancer Research and Treatment.
[80] Robin J. Leach,et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.
[81] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[82] Kwok-Kin Wong,et al. COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION , 2011, Nature Medicine.
[83] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[84] T. Helleday,et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links , 2009, Nucleic acids research.
[85] Xiaoling Li,et al. Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C , 2010, Proceedings of the National Academy of Sciences.
[86] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[87] Jeremy M. Stark,et al. 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.
[88] Z. Hořejší,et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. , 2010, Molecular cell.
[89] S. Elledge,et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.
[90] C. Deng,et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. , 2009, Molecular cell.
[91] Eric A. Hendrickson,et al. Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells , 2010, PLoS genetics.
[92] S. Sharan,et al. Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2 , 2008, Nature Medicine.
[93] L. Wessels,et al. Do predictive signatures really predict response to cancer chemotherapy? , 2010, Cell cycle.
[94] A. Krasnitz,et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. , 2009, Cancer cell.
[95] Michael C. Ostrowski,et al. Allele-specific tumor spectrum in Pten knockin mice , 2010, Proceedings of the National Academy of Sciences.
[96] Wang Yang. DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy , 2010 .
[97] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[98] E. Appella,et al. Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription , 2002, The EMBO journal.
[99] E. Shpall,et al. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? , 2009, Current opinion in oncology.
[100] David P. Lane,et al. Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.
[101] B. Koller,et al. Brca1 controls homology-directed DNA repair. , 1999, Molecular cell.
[102] Jorge S. Reis-Filho,et al. Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.
[103] J. Parvin,et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. , 2009, Molecular cell.
[104] N. Copeland,et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.
[105] Peter Bouwman,et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. , 2011, Cancer cell.
[106] Marcel J T Reinders,et al. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. , 2002, Cancer research.
[107] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[108] M. Protopopova,et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.
[109] H T Lynch,et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.
[110] Youngho Seo,et al. Selective activation of p53-mediated tumour suppression in high-grade tumours , 2010, Nature.
[111] Q. Waisfisz,et al. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. , 2003, Cancer research.
[112] William Arbuthnot Sir Lane,et al. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. , 2007, Molecular cell.
[113] Michael B Yaffe,et al. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.
[114] D. Neuberg,et al. Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy , 2004, Clinical Cancer Research.
[115] Fan Zhang,et al. PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2 , 2009, Molecular Cancer Research.
[116] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[117] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[118] Corbin E. Meacham,et al. In Vivo RNAi Screening Identifies Regulators of Actin Dynamics as Key Determinants of Lymphoma Progression , 2009, Nature Genetics.
[119] C. Deng,et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. , 2008, Molecular cell.
[120] G. Mills,et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. , 2008, Cancer research.
[121] A. Ashworth,et al. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment , 2012, Nature Reviews Clinical Oncology.
[122] M. Hollstein,et al. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.
[123] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[124] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[125] G. Evan,et al. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression , 2006, Nature.
[126] X. Wang,et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. , 2008, Cancer cell.
[127] M. Yaffe,et al. The combined status of ATM and p53 link tumor development with therapeutic response. , 2009, Genes & development.
[128] W. ElShamy,et al. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. , 2010, Cancer research.
[129] Y. A. Minamishima,et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. , 2000, Genes & development.
[130] B. Modan,et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[131] W. ElShamy,et al. Identification of BRCA1-IRIS, a BRCA1 locus product , 2004, Nature Cell Biology.
[132] Suhwan Chang,et al. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. , 2009, The Journal of clinical investigation.
[133] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[134] Feng Zhang,et al. PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response , 2009, Current Biology.
[135] J. Peterse,et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer , 2007, Proceedings of the National Academy of Sciences.
[136] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[137] David Cameron,et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.
[138] Eric F. Johnson,et al. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.
[139] D. Hanahan,et al. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. , 2010, Cancer cell.
[140] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[141] T. Jacks,et al. Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy , 2010, Proceedings of the National Academy of Sciences.
[142] B. Giraudeau,et al. ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer , 2005, Clinical Cancer Research.
[143] C. Brennan,et al. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. , 2010, Cancer cell.
[144] Elisabeth Brambilla,et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.
[145] Francisco J. Sánchez-Rivera,et al. Stage-specific sensitivity to p53 restoration during lung cancer progression , 2010, Nature.
[146] M. Sivasubramaniam,et al. Ku70 Corrupts DNA Repair in the Absence of the Fanconi Anemia Pathway , 2010, Science.
[147] Galina Selivanova,et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.
[148] W. Hahn,et al. Chemosensitivity linked to p73 function. , 2003, Cancer cell.
[149] S. Jackson,et al. Human SIRT6 Promotes DNA End Resection Through CtIP Deacetylation , 2010, Science.
[150] Lei Li,et al. Nucleotide Excision Repair- and Polymerase η-Mediated Error-Prone Removal of Mitomycin C Interstrand Cross-Links , 2003, Molecular and Cellular Biology.
[151] S. Elledge,et al. 53BP1, a Mediator of the DNA Damage Checkpoint , 2002, Science.
[152] R. Fleischmann,et al. Mutation of a mutL homolog in hereditary colon cancer. , 1994, Science.